|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
intrathecal injection
|
|
gptkbp:approves
|
gptkb:2004
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Prialt
|
|
gptkbp:chemical_formula
|
C60 H100 N18 O18 S
|
|
gptkbp:class
|
analgesic
|
|
gptkbp:clinical_trial
|
Phase III
well tolerated
effective for pain relief
|
|
gptkbp:clinical_use
|
pain management
|
|
gptkbp:contraindication
|
infection at injection site
hypersensitivity to ziconotide
|
|
gptkbp:developed_by
|
cone snail venom
|
|
gptkbp:drug_interactions
|
CNS depressants
opioids
|
|
gptkbp:duration
|
long-term
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:formulation
|
sterile solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ziconotide
|
|
gptkbp:indication
|
severe pain in patients who are intolerant to other treatments
|
|
gptkbp:ingredients
|
gptkb:ziconotide
|
|
gptkbp:lifespan
|
2.5 hours
|
|
gptkbp:manufacturer
|
gptkb:Elan_Pharmaceuticals
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
N-type calcium channel blocker
|
|
gptkbp:packaging
|
single-use vial
|
|
gptkbp:patient_population
|
adults
|
|
gptkbp:premiered_on
|
within hours
|
|
gptkbp:provides_guidance_on
|
pain management guidelines
|
|
gptkbp:research_areas
|
fibromyalgia
neuropathic pain
cancer pain
post-surgical pain
complex regional pain syndrome
|
|
gptkbp:route_of_administration
|
intrathecal
|
|
gptkbp:service_frequency
|
daily
|
|
gptkbp:side_effect
|
dizziness
headache
nausea
confusion
seizures
psychosis
mood changes
gastrointestinal issues
visual disturbances
somnolence
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:structure
|
gptkb:protein
|
|
gptkbp:targets
|
N-type calcium channels
|
|
gptkbp:used_for
|
chronic pain
|
|
gptkbp:weight
|
1184.5 g/mol
|
|
gptkbp:bfsParent
|
gptkb:Prialt
|
|
gptkbp:bfsLayer
|
7
|